Want to see HK:6821 full AI Analyst Report?
6821 Stock Chart & Stats
HK$73.80
-HK$0.50(-1.06%)
At close: 4:00 PM EST
HK$73.80
-HK$0.50(-1.06%)
Day’s Range― - ―
52-Week RangeHK$69.20 - HK$124.40
Previous CloseN/A
Volume191.84K
Average Volume (3M)640.69K
Market Cap
HK$61.70B
Enterprise ValueHK$31.80B
Total Cash (Recent Filing)HK$7.78B
Total Debt (Recent Filing)HK$238.99M
Price to Earnings (P/E)49.3
Beta1.27
Next Earnings
Aug 25, 2026Next Dividend Ex-DateN/A
Dividend Yield1.57%
Share Statistics
EPS (TTM)3.08
Shares Outstanding27,834,510
10 Day Avg. Volume442,016
30 Day Avg. Volume640,687
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)1.29
Price to Sales (P/S)3.40
P/FCF Ratio165.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$129.97Price Target Upside76.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)4.45
Revenue Forecast (FY)HK$9.22B
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Balance SheetExtremely low debt and a large equity base provide durable financial flexibility. This reduces bankruptcy risk, supports multi-year investments in GMP capacity and process development, and gives management optionality to pursue contracts or capex without heavy refinancing pressure.
Solid Operating MarginsSustained gross and net margins reflect differentiated CDMO capabilities and pricing power on specialized small‑molecule process work. Healthy margins support reinvestment for compliance and capacity, and provide a buffer versus cyclical topline swings in outsourcing demand.
Positive Revenue TrendMeaningful TTM revenue growth shows ongoing customer demand and successful project execution across development and manufacturing stages. Reliable top-line expansion supports longer-term capacity utilization and the potential conversion of development work into recurring commercial supply.
Bears Say
Weak Free Cash Flow ConversionThin FCF relative to net income and negative recent FCF growth reduce internal funds available for capex, dividends, or buybacks. Over months this constrains funding for growth initiatives and increases reliance on external financing or equity, limiting strategic flexibility.
Normalized Profitability Vs Prior PeaksMaterial step-down from prior peak margins indicates lasting margin pressure from mix shifts, pricing, or cost increases. If structural, this reduces return on capital and could require strategic changes to restore historical profitability, weighing on long-term returns.
Project-based Revenue And Potential LumpinessA revenue model reliant on discrete project fees and milestone payments creates lumpy, less predictable cash flows versus long-term supply contracts. This structural variability complicates capacity planning, working capital management, and near-term visibility into recurring revenue streams.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H News
6821 FAQ
What was Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price range in the past 12 months?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H lowest stock price was HK$69.20 and its highest was HK$124.40 in the past 12 months.
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap is HK$61.70B.
When is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date is Aug 25, 2026 which is in 53 days.
How were Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s earnings last quarter?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H released its earnings results on Apr 27, 2026. The company reported HK$0.963 earnings per share for the quarter, beating the consensus estimate of HK$0 by HK$0.963.
Is Asymchem Laboratories (Tianjin) Co., Ltd. Class H overvalued?
According to Wall Street analysts Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price is currently Undervalued.
Does Asymchem Laboratories (Tianjin) Co., Ltd. Class H pay dividends?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H pays a Annually dividend of HK$1.495 which represents an annual dividend yield of 1.57%. See more information on Asymchem Laboratories (Tianjin) Co., Ltd. Class H dividends here
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate is 0.
How many shares outstanding does Asymchem Laboratories (Tianjin) Co., Ltd. Class H have?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H has 27,834,510 shares outstanding.
What happened to Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price movement after its last earnings report?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H reported an EPS of HK$0.963 in its last earnings report, beating expectations of HK$0. Following the earnings report the stock price went up 5.634%.
Which hedge fund is a major shareholder of Asymchem Laboratories (Tianjin) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6821
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.63%
12-Months-Change
Fundamentals
Return on Equity
6.34%
Trailing 12-Months
Asset Growth
12.62%
Trailing 12-Months
Company Description
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a Contract Development and Manufacturing Organization (CDMO), offering its services to clients across Mainland China and internationally. The company delivers extensive drug research, development, and manufacturing solutions specifically tailored for pharmaceutical and biotechnology enterprises. Their offerings are comprehensive, covering the entire lifecycle from early clinical stages through to full commercialization, including R&D and cGMP compliant production of advanced intermediates, active pharmaceutical ingredients (APIs), and finished formulations, alongside clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the sale and distribution of medicinal products, and active participation in pharmaceutical science and technology innovation. The company was founded in 1999 and maintains its headquarters in Tianjin, China.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H (6821) Earnings & Revenues
6821 Stock 12 Month Forecast
Average Price Target
HK$129.97
▲(76.11% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―
Options Prices
Currently, No data available
---